> Cancer: development of ImMucin, a multi-epitope cancer vaccine to the MUC1 tumor associated antigen (TAA). ImMucin is currently being evaluated in a Phase I/II clinical trial in Multiple Myeloma patients scheduled to end in 2012.
Looks like similar timeframe to PRR.
http://www.vaxilbio.com/
vaccine targets 90pc of cancers, page-3
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.5¢ |
Change
-0.010(3.17%) |
Mkt cap ! $443.6M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.8¢ | 30.5¢ | $1.050M | 3.399M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 334744 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 5285 | 1 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |